CORC

在结果中检索

CORC

浏览/检索结果: 共21条，第1-10条 帮助

已选(0)清除 条数/页：   排序方式：
Long noncoding RNA Breast cancer antiestrogen resistance 4 is associated with cancer progression and its significant prognostic value. 期刊论文
Journal of cellular physiology, 2018
作者:  Zhao Wenqiu;  Wang Zhenlin;  Fang Xiao;  Li Na;  Fang Jian
收藏  |  浏览/下载：2/0  |  提交时间：2019/12/26
Autologous Fat Grafting as a Novel Antiestrogen Vehicle for the Treatment of Breast Cancer 期刊论文
2018, 卷号: 142, 期号: 4, 页码: 578E-579E
作者:  Ouyang, Yiye;  Li, Chengcheng;  Liu, Chunjun
收藏  |  浏览/下载：3/0  |  提交时间：2020/01/03
"Autologous Fat Grafting as a Novel Antiestrogen Vehicle for the Treatment of Breast Cancer: Advantages and Technical Drawbacks." 期刊论文
2018
作者:  Ouyang Yiye;  Li Chengcheng;  Liu Chunjun
收藏  |  浏览/下载：2/0  |  提交时间：2020/01/03
Combined action of estrogen receptor agonists and antagonists in two-hybrid recombinant yeast in vitro 期刊论文
ECOTOXICOLOGY AND ENVIRONMENTAL SAFETY, 2015, 卷号: 111, 页码: 228-235
作者:  Yang, Rong;  Li, Na;  Rao, Kaifeng;  Ma, Mei;  Wang, Zijian
收藏  |  浏览/下载：15/0  |  提交时间：2016/03/11
A phase III study of fulvestrant 500 mg versus 250 mg in postmenopausal Chinese women with advanced breast cancer and disease progression following failure on prior antiestrogen or aromatase inhibitor therapy: Supporting superior clinical benefit for the 会议论文
作者:  Jiang, Zefei;  Zhang, Qingyuan;  Shao, Zhimin;  Shen, Kunwei;  Li, Li
收藏  |  浏览/下载：59/0  |  提交时间：2019/12/13
A phase III study of fulvestrant 500 mg versus 250 mg in postmenopausal Chinese women with advanced breast cancer and disease progression following failure on prior antiestrogen or aromatase inhibitor therapy: Supporting superior clinical benefit for the 期刊论文
Cancer Research, 2015, 卷号: 75
作者:  Jiang Z., Zhang Q., Shao Z., Shen K., Li L., Feng J., Tong Z., Gu K., Wang X., Xu B., Sun G., Chen H., Rukazenkov Y.
收藏  |  浏览/下载：4/0  |  提交时间：2019/12/19
A phase III study of fulvestrant 500 mg versus 250 mg in postmenopausal Chinese women with advanced breast cancer and disease progression following failure on prior antiestrogen or aromatase inhibitor therapy: Supporting superior clinical benefit 期刊论文
2015, 卷号: 75
作者:  Jiang, Zefei;  Zhang, Qingyuan;  Shao, Zhimin;  Shen, Kunwei;  Li, Li
收藏  |  浏览/下载：59/0  |  提交时间：2020/01/04
A phase III study of fulvestrant 500 mg versus 250 mg in postmenopausal Chinese women with advanced breast cancer and disease progression following failure on prior antiestrogen or aromatase inhibitor therapy: Supporting superior clinical benefit 会议论文
CANCER RESEARCH, 2015-05-01
作者:  Jiang, Zefei;  Zhang, Qingyuan;  Shao, Zhimin;  Shen, Kunwei;  Li, Li
收藏  |  浏览/下载：8/0  |  提交时间：2020/01/04
A771726, an anti-inflammatory drug, exerts an anticancer effect and reverses tamoxifen resistance in endocrine-resistant breast cancer cells 期刊论文
ONCOLOGY REPORTS, 2014, 卷号: 32, 期号: 2, 页码: 627-634
作者:  Huang, Ou;  Xie, Zuoquan;  Zhang, Weili;  Lou, Ying;  Mao, Yan
收藏  |  浏览/下载：14/0  |  提交时间：2019/01/08
ER-α variant ER-α36 mediates antiestrogen resistance in ER-positive breast cancer stem/progenitor cells 期刊论文
Journal of Steroid Biochemistry and Molecular Biology, 2014, 卷号: 144, 期号: PART B, 页码: e417-e426
作者:  Deng H.;  Yin L.;  Zhang X.-T.;  Liu L.-J.;  Wang M.-L.
收藏  |  浏览/下载：3/0  |  提交时间：2019/12/17

©版权所有 ©2017 CSpace - Powered by CSpace